---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008443"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:52:31.020491+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio enters retention agreements with senior management amid strategic review

## Summary
- Retention agreements cover CEO, CFO, and other senior executives, providing lump sum cash equal to 50% of annual base salary upon qualifying termination or Feb 22, 2024.
- 50% acceleration of unvested equity awards granted in 2023 on qualifying termination after June 30, 2023.
- Stock option exercise period extended to 12 months post-termination or original expiry.
- Strategic alternatives process is ongoing; retention agreements designed to retain key talent.

## SEC filing metadata
- accession: 0000950170-23-008443
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017023008443/0000950170-23-008443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017023008443/grph-20230310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008443
- JSON: https://secwatch.observer/filing/0000950170-23-008443.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008443.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.